Disease Domain | Count |
---|---|
Nervous System Diseases | 5 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Gene therapy | 7 |
AAV based gene therapy | 5 |
Target |
Mechanism micro-dystrophin stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism micro-dystrophin modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FXN modulators |
Active Org. |
Originator Org. Aavantibio, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 May 2024 |
Sponsor / Collaborator |
Start Date13 Oct 2022 |
Sponsor / Collaborator |
Start Date20 Sep 2018 |
Sponsor / Collaborator Pfizer Inc. [+11] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
SGT-003 ( micro-dystrophin ) | Muscular Dystrophy, Duchenne More | Phase 2 Clinical |
SGT-001 ( micro-dystrophin ) | Muscular Dystrophy, Duchenne More | Phase 2 Clinical |
UX-810 ( dystrophin ) | Muscular Dystrophy, Duchenne More | Preclinical |
AVB-501 | Cardiomyopathy, Dilated More | Preclinical |
AVB-401 ( BAG3 ) | BAG3 mediated Dilated Cardiomyopathy More | Preclinical |